Home » Dr. Reddy’s to Acquire Mayne Pharma U.S. Generics Portfolio
Dr. Reddy’s to Acquire Mayne Pharma U.S. Generics Portfolio
Dr. Reddy’s Laboratories subsidiary plans to broaden its generic drug portfolio through the purchase of Australia-based Mayne Pharma’s U.S. generic prescription products.
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products.
Many of the products are focused on women’s health, including a hormonal vaginal ring and a birth control pill.
Mayne Pharma will receive an upfront payment of approximately $90 million and contingent payments of up to $15 million.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May